Načítá se...
Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
For decades, treatment of chronic lymphocytic leukemia (CLL) has been based on chemotherapy. This changed when the first CD20 antibody rituximab was introduced. Since 2008, the combination of chemotherapy and CD20 antibodies has become the standard of care for most patients, and a significant fracti...
Uloženo v:
| Vydáno v: | Drug Des Devel Ther |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5279834/ https://ncbi.nlm.nih.gov/pubmed/28182141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S104869 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|